ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ZEG - GB0009895292 - Common Stock
157.25 EUR
+1.3 (+0.83%)
Overall ZEG gets a fundamental rating of 5 out of 10. We evaluated ZEG against 54 industry peers in the Pharmaceuticals industry. While ZEG has a great profitability rating, there are quite some concerns on its financial health. ZEG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
In the past year ZEG had a positive cash flow from operations.
Each year in the past 5 years ZEG has been profitable.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
ZEG's Return On Assets of 8.21% is fine compared to the rest of the industry. ZEG outperforms 66.67% of its industry peers.
Looking at the Return On Equity, with a value of 20.48%, ZEG is in the better half of the industry, outperforming 70.37% of the companies in the same industry.
With a decent Return On Invested Capital value of 14.42%, ZEG is doing good in the industry, outperforming 72.22% of the companies in the same industry.
ZEG had an Average Return On Invested Capital over the past 3 years of 11.62%. This is below the industry average of 13.79%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
With a decent Profit Margin value of 16.17%, ZEG is doing good in the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Profit Margin of ZEG has grown nicely.
Looking at the Operating Margin, with a value of 24.34%, ZEG is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
In the last couple of years the Operating Margin of ZEG has grown nicely.
ZEG's Gross Margin of 81.90% is amongst the best of the industry. ZEG outperforms 83.33% of its industry peers.
ZEG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZEG is creating some value.
The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ZEG has more shares outstanding
The debt/assets ratio for ZEG is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.03 indicates that ZEG is not in any danger for bankruptcy at the moment.
The Altman-Z score of ZEG (6.03) is better than 81.48% of its industry peers.
The Debt to FCF ratio of ZEG is 3.41, which is a good value as it means it would take ZEG, 3.41 years of fcf income to pay off all of its debts.
ZEG has a Debt to FCF ratio (3.41) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.61 indicates that ZEG is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.61, ZEG is in line with its industry, outperforming 46.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 6.03 |
ROIC/WACC1.58
WACC9.11%
2.3 Liquidity
A Current Ratio of 0.88 indicates that ZEG may have some problems paying its short term obligations.
ZEG has a worse Current ratio (0.88) than 81.48% of its industry peers.
ZEG has a Quick Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ZEG (0.69) is worse than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.61% over the past year.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
The Earnings Per Share is expected to grow by 12.45% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.17% on average over the next years.
EPS Next Y14.12%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
EPS Next 5Y12.45%
Revenue Next Year10.13%
Revenue Next 2Y8.09%
Revenue Next 3Y7.31%
Revenue Next 5Y7.17%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.29, ZEG is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.59, ZEG is valued a bit cheaper.
The Price/Forward Earnings ratio is 17.44, which indicates a rather expensive current valuation of ZEG.
The rest of the industry has a similar Price/Forward Earnings ratio as ZEG.
When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (24.03), we can say ZEG is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.29 | ||
| Fwd PE | 17.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZEG is valued a bit more expensive than the industry average as 68.52% of the companies are valued more cheaply.
ZEG's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. ZEG is more expensive than 64.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 60.07 | ||
| EV/EBITDA | 28.85 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
A more expensive valuation may be justified as ZEG's earnings are expected to grow with 13.01% in the coming years.
PEG (NY)1.44
PEG (5Y)1.09
EPS Next 2Y13.77%
EPS Next 3Y13.01%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 1.81%. Purely for dividend investing, there may be better candidates out there.
ZEG's Dividend Yield is comparable with the industry average which is at 1.85.
ZEG's Dividend Yield is comparable with the S&P500 average which is at 1.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
FRA:ZEG (12/23/2025, 7:00:00 PM)
157.25
+1.3 (+0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap487.56B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend2.55
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)5.72%
PT rev (3m)5.39%
EPS NQ rev (1m)-1.11%
EPS NQ rev (3m)-3.63%
EPS NY rev (1m)0.29%
EPS NY rev (3m)0.38%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)0.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.29 | ||
| Fwd PE | 17.44 | ||
| P/S | 9.89 | ||
| P/FCF | 60.07 | ||
| P/OCF | 37.96 | ||
| P/B | 12.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.85 |
EPS(TTM)7.75
EY4.93%
EPS(NY)9.02
Fwd EY5.73%
FCF(TTM)2.62
FCFY1.66%
OCF(TTM)4.14
OCFY2.63%
SpS15.91
BVpS12.56
TBVpS-3.7
PEG (NY)1.44
PEG (5Y)1.09
Graham Number46.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 6.03 |
F-Score7
WACC9.11%
ROIC/WACC1.58
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y14.12%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.13%
Revenue Next 2Y8.09%
Revenue Next 3Y7.31%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.11%
EBIT Next 3Y17.46%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 20.29 and the Price/Book (PB) ratio is 12.52.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.